Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.100
-0.010 (-0.24%)
At close: Mar 28, 2025, 4:00 PM
3.910
-0.190 (-4.64%)
Pre-market: Mar 31, 2025, 8:48 AM EDT

Company Description

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.

The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.

The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics, Inc.
Lexeo Therapeutics logo
Country United States
Founded 2017
IPO Date Nov 3, 2023
Industry Biotechnology
Sector Healthcare
Employees 72
CEO R. Townsend

Contact Details

Address:
345 Park Avenue South, 6th Floor
New York, New York 10010
United States
Phone 212 547 9879
Website lexeotx.com

Stock Details

Ticker Symbol LXEO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001907108
CUSIP Number 52886X107
ISIN Number US52886X1072
Employer ID 85-4012572
SIC Code 2836

Key Executives

Name Position
R. Nolan Townsend Chief Executive Officer and Director
Dr. Eric Adler M.D. Chief Medical Officer and Head of Research
Jenny R. Robertson J.D. Chief Business and Legal Officer
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board
Dr. Kyle Rasbach Ph.D., Pharm.D. Chief Financial Officer
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer
Dr. Sandi See Tai M.D. Chief Development Officer
Ryan McHenry Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Mar 24, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 24, 2025 424B5 Filing
Mar 24, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing